Secukinumab may be remedy for systemic amyloidosis findings secondary to hidradenitis suppurativa

Gamze Tas-Aygar; Muzeyyen Gonul; Ibrahim Ozcan; Mehmet Deniz Ayli; Dilek Ertoy-Baydar

doi:10.1111/dth.14205

Secukinumab may be remedy for systemic amyloidosis findings secondary to hidradenitis suppurativa

Dermatol Ther. 2020 Nov;33(6):e14205. doi: 10.1111/dth.14205. Epub 2020 Sep 11.

Authors

Gamze Tas-Aygar¹, Muzeyyen Gonul¹, Ibrahim Ozcan², Mehmet Deniz Ayli³, Dilek Ertoy-Baydar⁴

Affiliations

¹ University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Dermatology Clinic, Ankara, Turkey.
² University of Health Sciences, Dr. Sami Ulus Obstetrics and Gynecology, Pediatric Health and Disease Training and Research Hospital, Ankara, Turkey.
³ University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Nephrology Clinic, Ankara, Turkey.
⁴ Koc University, Pathology Clinic, İstanbul, Turkey.

PMID: 32829493
DOI: 10.1111/dth.14205

Abstract

Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory disease of follicular epithelium; many comorbidities occur that disrupt the quality of life of patients. Amyloidosis is one of them. We present a case with systemic amyloidosis secondary to HS and responding positively to secukinumab therapy. Secukinumab may also be an important option for amyloidosis findings in HS patients.

Keywords: amyloidosis; hidradenitis suppurativa; secukinumab.

MeSH terms

Amyloidosis* / diagnosis
Amyloidosis* / drug therapy
Amyloidosis* / etiology
Antibodies, Monoclonal, Humanized
Hidradenitis Suppurativa* / complications
Hidradenitis Suppurativa* / diagnosis
Hidradenitis Suppurativa* / drug therapy
Humans
Quality of Life

Substances

Antibodies, Monoclonal, Humanized
secukinumab